All the news Showing 10 of 93 articles from: HCV and coinfectionsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Leading Canadian researcher calls for inclusion of co-infected people in large HCV clinical trials CATIE / 07 July 2015 Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection Liz Highleyman / 04 March 2015 A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis C for more than 95% of ... People living with HIV have high survival rates after liver transplants due to HCC Keith Alcorn / 12 November 2014 People with HIV – most of whom had hepatitis B or C co-infection – generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with five-year survival rates similar to those ... Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection Liz Highleyman / 10 November 2014 All but one participant treated for hepatitis C virus (HCV) with a co-formulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment, in a study involving people with ... People living with HIV in the US are infrequently screened for HCV Michael Carter / 24 September 2014 People living with HIV are infrequently screened for hepatitis C virus (HCV) infection, according to US research published in the online edition of Clinical Infectious Diseases. The retrospective study examined screening practices ... Even moderate drinking increases risk of advanced liver fibrosis for people with HIV and HCV co-infection Michael Carter / 28 May 2014 Even moderate alcohol consumption is associated with an increased risk of advanced liver fibrosis for people living with HIV and hepatitis C virus (HCV) co-infection, investigators from the United States report in Clinical ... MK-5172 + MK-8742 demonstrate good early post-treatment response rates Liz Highleyman / 24 April 2014 A combination of two direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for people with genotype 1 hepatitis C virus (HCV), including ... Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection Liz Highleyman / 11 April 2014 Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1 hepatitis C virus ... Jurgen Rockstroh: Hepatitis highlights from CROI 2014 NATAP / 24 March 2014 Antiretroviral therapy reduces liver decompensation risk in HIV/HCV coinfected patients HIVandHepatitis.com / 21 February 2014 ← Prev1...45678...10Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds